-
Mashup Score: 24Daratumumab in pediatric relapsed/refractory acute lymphoblastic leukemia or lymphoblastic lymphoma: the DELPHINUS study - 5 hour(s) ago
Key PointsDaratumumab plus chemotherapy may effectively bridge children and young adults with relapsed/refractory T-cell ALL/LL to HSCT.No new safety conce
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1Mitochondrial dsRNA from B-ALL cells stimulates mesenchymal stromal cells to become cancer-associated fibroblasts - 6 day(s) ago
Key PointsExposure of MSCs to B-ALL cell lines triggers CAF formation.The proximate trigger for CAF formation is ALL-derived mitochondrial dsRNA.
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
The proximate trigger for CAF formation is ALL-derived mitochondrial dsRNA. https://t.co/QJMZmLED2W #lymphoidneoplasia https://t.co/w7wApsq5em
-
-
Mashup Score: 14Location, location, location: EMD in MM - 6 day(s) ago
In this issue of Blood, John et al apply spatial transcriptomics to gain insights into the spatial complexity of extramedullary disease (EMD) in multiple m
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
Location, location, location: EMD in MM https://t.co/YqexiL1gpA #lymphoidneoplasia https://t.co/JKYLFZn0Ze
-
-
Mashup Score: 13NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLLr B-ALL by regulating NR3C1 expression - 13 day(s) ago
Key PointsNG2 is an epigenetically regulated direct target gene of the leukemic MLL-AF4 fusion protein.NG2 negatively regulates the expression of the gluco
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
NG2 negatively regulates the expression of the glucocorticoid receptor NR3C1, conferring glucocorticoid resistance to MLLr B-ALL cells. https://t.co/YDAuPPtQZE #lymphoidneoplasia https://t.co/4V1gP3W6Nu
-
-
Mashup Score: 13NG2 at the core: tackling MLLr B-ALL resistance - 13 day(s) ago
In this issue of Blood, Lopez-Millan et al1 identified a novel pathway involved in the poor response to glucocorticoids in MLL (KMT2A) rearranged B-precurs
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
NG2 at the core: tackling MLLr B-ALL resistance https://t.co/kTpToYXvOW #lymphoidneoplasia https://t.co/EhTGx1ThPE
-
-
Mashup Score: 43Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis - 14 day(s) ago
Abstract. Recent introduction of 2 different lymphoma classifications has raised concerns about consistency in diagnosis, management, and clinical trial en
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysis https://t.co/CqNUEbIm1J #lymphoidneoplasia
-
-
Mashup Score: 3Impact of PIK3CA gain and PTEN loss on mantle cell lymphoma biology and sensitivity to targeted therapies - 15 day(s) ago
Key PointsPIK3CA gain and PTEN loss decrease the dependence of MCL cells on BCR signaling and antiapoptotic BCL2.PIK3CA gain and PTEN loss lead to complex
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
PIK3CA gain and PTEN loss decrease the dependence of MCL cells on BCR signaling and antiapoptotic BCL2. https://t.co/cLsAoRnRhg #lymphoidneoplasia https://t.co/gJRtDjY7ZD
-
-
Mashup Score: 23
Key PointsThe 2-year progression-free survival of 58 patients with T-cell/histiocyte–rich large B-cell lymphoma treated with CD19-CART therapy was 29%.
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
The 2-year progression-free survival of 58 patients with T-cell/histiocyte–rich large B-cell lymphoma treated with CD19-CART therapy was 29%. https://t.co/GI12k2Kvir #lymphoidneoplasia https://t.co/Eki0bp3iXw
-
-
Mashup Score: 25Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy - 19 day(s) ago
Key PointsTAFA combined with LEN showed limited efficacy after CAR T-cell failure in a high-risk population.Outcomes were comparable between the TAFA-LEN c
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
TAFA combined with LEN showed limited efficacy after CAR T-cell failure in a high-risk population. https://t.co/25bgAqc3B8 #lymphoidneoplasia https://t.co/HedEc6ZviR
-
-
Mashup Score: 39Outcome of patients with large B-cell lymphoma treated with tafasitamab plus lenalidomide either before or after CAR T-cell therapy - 22 day(s) ago
Key PointsTAFA combined with LEN showed limited efficacy after CAR T-cell failure in a high-risk population.Outcomes were comparable between the TAFA-LEN c
Source: ashpublications.orgCategories: General Medicine News, Oncologists1Tweet-
Outcomes were comparable between the TAFA-LEN combination and other treatments for the first progression after CAR T-cell therapy. https://t.co/GteBMfGHML #lymphoidneoplasia https://t.co/IrbL8pc8s2
-
No new safety concerns were identified with daratumumab treatment in children and young adults with B-cell ALL or T-cell ALL/LL. https://t.co/vYYfhcycvC #lymphoidneoplasia https://t.co/aD37oYAjLi